Brand names: BOSULIF
Bosutinib is indicated for:
Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)
Irrespective of gender only Adults (18 years old or older)
Bosutinib is indicated for the treatment of adult patients with:
- newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
- CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 400-500 mg once daily
Active ingredient Bosutinib is contraindicated in the following cases: